High-Dose

ApprovedSmall molecule

XXiangbei Welman Pharmaceutical Co., Ltd

High-Dose is one of 135 small molecule programs targeting Acute Myocardial Infarction. It is currently in Approved.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

InfluenzaActive, not recruiting

Diabetes Mellitus, Type 2Completed

Disc Degenerative DiseaseNot yet recruiting

Urinary Tract InfectionActive, not recruiting

Acute Myocardial InfarctionPhase 2

Active, not recruiting

InfluenzaPhase 1

Active, not recruiting

Diabetes Mellitus, Type 2Approved

Completed

Disc Degenerative DiseasePreclinical

Not yet recruiting

Recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

High-Dose

XXiangbei Welman Pharmaceutical Co., Ltd

Approved

1 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

COMIRNATY

Pfizer

Preclinical

1 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Age-Related Macular Degeneration

NCT07668804

Q4 2030

PreclinicalNot yet recruiting

Disc Degenerative Disease

NCT07668466

Clinical

Trials by Indication[1]

Apnea of Prematurity1 trial

Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It.

Active, not recruiting·NNishtar Medical University·Phase 1·NCT06905496·114 enrolled

Pancreas Cancer1 trial

High-dose Vitamin D3 in Pancreas Cancer

Terminated·MMedical University of Graz·Phase 3·NCT03472833·25 enrolled

Safety and Efficacy1 trial

A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults

Completed·UUniversity of Missouri-Columbia·Phase 1/2·NCT00549523·133 enrolled

Urinary Tract Infection1 trial

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Suspended·XXiangbei Welman Pharmaceutical Co., Ltd·Phase 2·NCT01601093·288 enrolled

Acute Myocardial Infarction1 trial

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Completed·BBeijing Northland Biotech. Co., Ltd.·Phase 2·NCT05485818·62 enrolled

7 more indications

Double-blind1 trial

A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

Completed·HHoly Stone Healthcare Co., Ltd·Phase 2·NCT02493712·51 enrolled

Clinical Trial1 trial

Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 2·NCT07035054·992 enrolled

Influenza1 trial

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Completed·KKBio Inc·Phase 1·NCT04439695·120 enrolled

Graves disease1 trial

Comparative Study of Different I-131 Doses in Graves' Disease

Unknown status·MMashhad University of Medical Sciences·N/A·NCT02114619·450 enrolled

Diabetes Mellitus, Type 21 trial

THE EFFECT OF LUMBRICUS RUBELLUS DLBS1033 EXTRACT ON LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN, VASCULAR ENDOTHELIAL GROWTH FACTOR, AND QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Completed·UUniversitas Sebelas Maret·Approved·NCT07684625·60 enrolled

Age-Related Macular Degeneration1 trial

A Phase I/IIa Trial to Evaluate the Safety, Tolerability and Efficacy After Single Administration of TO-O-1007 (Intravitreal Implant) in Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting·TTheratocular Biotek Co.·Preclinical·NCT07668804·31 enrolled

Disc Degenerative Disease1 trial

A Phase I/II, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

Not yet recruiting·CCartago Biotech Pty Ltd·Preclinical·NCT07668466·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for High-Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High-Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High-Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiangbei Welman Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: XXiangbei Welman Pharmaceutical Co., Ltd

High-Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Apnea of Prematurity1 trial

Pancreas Cancer1 trial

Safety and Efficacy1 trial

Urinary Tract Infection1 trial

Acute Myocardial Infarction1 trial

Double-blind1 trial

Clinical Trial1 trial

Influenza1 trial

Graves disease1 trial

Diabetes Mellitus, Type 21 trial

Age-Related Macular Degeneration1 trial

Disc Degenerative Disease1 trial

References

Drug Info

Quick Facts

Related News